Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer
November 28 2023 - 8:30AM
Business Wire
Apyx Medical Corporation (Nasdaq:APYX) (“Apyx Medical;” the
“Company”), the manufacturer of a proprietary helium plasma and
radiofrequency technology marketed and sold as Renuvion®, today
announced the appointment of Matthew Hill to the position of Chief
Financial Officer, effective December 4, 2023. Mr. Hill succeeds
Tara Semb, whose departure was announced by the Company on November
9, 2023.
“Matt joins our executive leadership team with over 30 years of
financial and operational experience, more than 20 years of which
has been in the healthcare industry, where he has served as the
Chief Financial Officer of four publicly-traded healthcare
companies,” said Charlie Goodwin, President and Chief Executive
Officer of Apyx Medical. “I’m pleased to welcome Matt to Apyx
Medical and look forward to working with him to execute our
strategic initiatives and position the Company to deliver strong,
sustainable, long-term growth.”
“With its innovative Renuvion technology, large, global market
opportunity, recent operational progress and an enhanced balance
sheet, I believe Apyx Medical is well-positioned for future success
in the cosmetic surgery market,” said Mr. Hill. “I am pleased to
join the Company at this exciting time, and look forward to working
with Charlie and the rest of the team as we lead Apyx Medical
through its next stage of growth and development.”
Mr. Hill joins Apyx Medical from PDS Biotechnology Corporation
(Nasdaq: PDSB; “PDS Biotech”), a clinical-stage immunotherapy
company, where he served as Chief Financial Officer, leading all
aspects of the company’s budgeting, forecasting, financial
management and reporting. Prior to joining PDS Biotech, he served
as Chief Financial Officer of Strata Skin Sciences (Nasdaq: SSKN),
a medical technology company developing, commercializing and
marketing products for the treatment of dermatologic conditions,
from 2018 to 2021.
Prior to joining Strata Skin Sciences, Mr. Hill held CFO roles
at several companies, including Velcera, Inc., which developed pet
medication for the companion animal health industry, and EP
MedSystems, which developed and marketed cardiac electrophysiology
products. He was also a Senior Manager at the international
accounting and consulting firm, Grant Thornton LLP. Mr. Hill holds
a Bachelor of Science in Accounting from Lehigh University.
About Apyx Medical
Corporation:
Apyx Medical Corporation is an advanced energy technology
company with a passion for elevating people’s lives through
innovative products, including its Helium Plasma Technology
products marketed and sold as Renuvion® in the cosmetic surgery
market and J-Plasma® in the hospital surgical market. Renuvion® and
J-Plasma® offer surgeons a unique ability to provide controlled
heat to tissue to achieve their desired results. The Company also
leverages its deep expertise and decades of experience in unique
waveforms through OEM agreements with other medical device
manufacturers. For further information about the Company and its
products, please refer to the Apyx Medical Corporation website at
www.ApyxMedical.com.
Cautionary Statement on Forward-Looking
Statements:
Certain matters discussed in this release and oral statements
made from time to time by representatives of the Company may
constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 and the Federal
securities laws. Although the Company believes that the
expectations reflected in such forward-looking statements are based
upon reasonable assumptions, it can give no assurance that its
expectations will be achieved.
All statements other than statements of historical fact are
statements that could be deemed forward-looking statements,
including but not limited to, projections of net revenue, margins,
expenses, net earnings, net earnings per share, or other financial
items; projections or assumptions concerning the possible receipt
by the Company of any regulatory approvals from any government
agency or instrumentality including but not limited to the U.S.
Food and Drug Administration (the “FDA”), supply chain disruptions,
component shortages, manufacturing disruptions or logistics
challenges; or macroeconomic or geopolitical matters and the impact
of those matters on the Company’s financial performance.
Forward-looking statements and information are subject to
certain risks, trends and uncertainties that could cause actual
results to differ materially from those projected. Many of these
factors are beyond the Company’s ability to control or predict.
Important factors that may cause the Company’s actual results to
differ materially and that could impact the Company and the
statements contained in this release include but are not limited to
risks, uncertainties and assumptions relating to the regulatory
environment in which the Company is subject to, including the
Company’s ability to gain requisite approvals for its products from
the FDA and other governmental and regulatory bodies, both
domestically and internationally; the impact of the March 14, 2022
FDA Safety Communication on our business and operations; sudden or
extreme volatility in commodity prices and availability, including
supply chain disruptions; changes in general economic, business or
demographic conditions or trends; changes in and effects of the
geopolitical environment; liabilities and costs which the Company
may incur from pending or threatened litigations, claims, disputes
or investigations; and other risks that are described in the
Company’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2022 and the Company’s other filings with the
Securities and Exchange Commission. For forward-looking statements
in this release, the Company claims the protection of the safe
harbor for forward-looking statements contained in the Private
Securities Litigation Reform Act of 1995. The Company assumes no
obligation to update or supplement any forward-looking statements
whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231128332429/en/
Investor Relations Contact:
ICR Westwicke on behalf of Apyx Medical Corporation Mike Piccinino,
CFA investor.relations@apyxmedical.com
Apyx Medical (NASDAQ:APYX)
Historical Stock Chart
From Apr 2024 to May 2024
Apyx Medical (NASDAQ:APYX)
Historical Stock Chart
From May 2023 to May 2024